Shift to Safety: Why Top Fund Managers are Betting on Pharma Amid Global Tensions
Source: Economictimes
Arth Insight · What this means for your wallet
- Your existing investments in IT and Metals might see slower growth or potential dips due to global uncertainties.
- Shifting to Pharma/Healthcare can offer more stability and protect your capital from sharp market downturns.
- This move aims to preserve your wealth by favouring sectors less affected by inflation and geopolitical risks.
Wealth-Impact Simulator
See what a one-time investment could grow to.
Indicative estimate for education only — not investment advice.
Explore investmentsAs West Asian conflicts and US inflation create a volatile environment for Indian stocks, experts are moving toward defensive sectors. Investors are advised to be cautious with IT and Metals while looking at Healthcare for stability.
- ▸Global tensions in West Asia and US inflation are creating a 'risk-off' environment for Indian equities.
- ▸Pharma and Healthcare are currently seen as the safest 'defensive' sectors for retail investors.
- ▸IT services face long-term structural issues, while Metals require profit-booking due to high volatility.
- ✓Global tensions in West Asia and US inflation are creating a 'risk-off' environment for Indian equities.
- ✓Pharma and Healthcare are currently seen as the safest 'defensive' sectors for retail investors.
- ✓IT services face long-term structural issues, while Metals require profit-booking due to high volatility.
A Challenging Global Backdrop
Indian equity markets are navigating a period of significant uncertainty as external pressures begin to weigh on local sentiment. Harsha Upadhyaya, Chief Investment Officer at Kotak AMC, suggests that the current environment is not ideal for aggressive risk-taking. The primary headwinds include escalating tensions between Iran and the US in West Asia, alongside persistent inflation in the United States, which has dampened hopes for immediate interest rate cuts.
Defensive Rotation: The Case for Pharma
In response to this volatility, there is a visible strategic shift toward 'defensive' sectors—industries that tend to remain stable regardless of the economic climate. Pharma and healthcare have emerged as the preferred havens for fund managers. Unlike cyclical sectors, healthcare demand remains consistent, providing a cushion for retail portfolios when the broader market faces selling pressure.
Caution in IT and Metals
The outlook for the Information Technology (IT) and Metals sectors remains cautious for the following reasons:
- IT Services: The sector is grappling with structural slowdowns. As global companies tighten their discretionary spending due to economic uncertainty, Indian IT firms are seeing a direct impact on their growth trajectories.
- Metals: Experts advise trimming positions in metal stocks. These are highly sensitive to global commodity cycles and geopolitical shifts, making them risky bets in the current high-tension climate.
Monitoring Foreign Flows
A critical factor for the Indian market's direction will be the behavior of Foreign Portfolio Investors (FPIs). While domestic liquidity remains strong, foreign flows are sensitive to US bond yields and global geopolitical developments. Any sustained pull-out by foreign investors could lead to short-term corrections, making it essential for retail investors to avoid over-leveraged positions.
Conclusion
While the long-term India story remains intact, the short-term path is cluttered with global macro challenges. For retail investors, the current mantra is rotation rather than exit—moving away from high-beta sectors like Metals and troubled sectors like IT, and parking capital in more resilient spaces like Healthcare to weather the storm.
Investment in securities market are subject to market risks. Read all the related documents carefully before investing. This content is for informational purposes only and does not constitute financial advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about Stock Market
IPOBreakingIPO Grey Market Trends: LEAP India, Technocraft Ventures, and Dhoot Transmission Updates
Three major IPOs from LEAP India, Technocraft Ventures, and Dhoot Transmission are set to hit the primary market this week. Investors are closely monitoring Grey Market Premiums (GMP) to gauge potential listing gains across the logistics and infrastructure sectors.
IPOBreakingH.R. Hygiene Products IPO Lists Today on BSE SME; Modest Listing Gain Expected
H.R. Hygiene Products makes its debut on the BSE SME platform today, following an IPO that was subscribed 6.26 times. The grey market premium (GMP) suggests a small listing gain of around 1% over the upper issue price of ₹88.
IPOBreakingManipal Health Shares List at 11% Premium: Investors Book Gains on Market Debut
Manipal Health made a positive debut on the stock exchanges today, listing at a premium of over 11% against its issue price. The shares opened at ₹652 on the NSE and ₹655 on the BSE, rewarding successful allottees with immediate listing gains.
Related Stories
IPOBreakingIPO Grey Market Trends: LEAP India, Technocraft Ventures, and Dhoot Transmission Updates
Three major IPOs from LEAP India, Technocraft Ventures, and Dhoot Transmission are set to hit the primary market this week. Investors are closely monitoring Grey Market Premiums (GMP) to gauge potential listing gains across the logistics and infrastructure sectors.
IPOBreakingH.R. Hygiene Products IPO Lists Today on BSE SME; Modest Listing Gain Expected
H.R. Hygiene Products makes its debut on the BSE SME platform today, following an IPO that was subscribed 6.26 times. The grey market premium (GMP) suggests a small listing gain of around 1% over the upper issue price of ₹88.
IPOBreakingManipal Health Shares List at 11% Premium: Investors Book Gains on Market Debut
Manipal Health made a positive debut on the stock exchanges today, listing at a premium of over 11% against its issue price. The shares opened at ₹652 on the NSE and ₹655 on the BSE, rewarding successful allottees with immediate listing gains.
IPOBreakingMolbio Diagnostics IPO: Price Band ₹768-₹807, Opens Aug 10
Molbio Diagnostics has announced its Initial Public Offering (IPO) with a price band set between ₹768 and ₹807 per share. The subscription period will be open from August 10 to August 12.